1.Risk factors associated with repeat Radioactive Iodine Therapy for differentiated Thyroid Cancer in a tertiary care center in the Philippines: A retrospective cohort study
Waynila Mae P. Lim-Cuizon ; Imelda Lagula-Bilocura
Philippine Journal of Internal Medicine 2018;56(3):136-142
Introduction:
Thyroid carcinoma remains the most common endocrine malignancy and incidence has increased due to improved diagnosis. Most Differentiated Thyroid Cancers (DTC) are indolent and easily cured with surgery, radioactive iodine (RAI) therapy and TSH suppression. However, persistent and recurrent disease is not uncommon among Filipinos. RAI therapy is being used more frequently even for low risk patients due to this observed aggressiveness of DTC in our population. This study sought to identify factors that are associated with failure of initial RAI for DTC, leading to repeat doses.
Methods:
This is a single-center, retrospective cohort study conducted in the Nuclear Medicine Department of a tertiary care center in the Philippines, involving 325 patients who underwent RAI from 2006-2016
Results:
Out of 570 patients who underwent RAI therapy for DTC, only 325 were included. Majority (n=280, 86%) had PTC and the rest had FTC (n=45, 14%). Twenty four percent (n=67) of the PTC group and 31% (n=14) of the FTC had subsequent RAI therapy after initial therapy due to either persistent or recurrent disease, with a mean interval of 21-22 months. Distant metastasis at presentation (M1), uptake in distant tissues on the initial post-therapy whole body scan (WBS) and TNM stage 4 were predictive for repeat RAI for FTC. A negative post-therapy WBS was found to be associated with no need for repeat RAI. On the other hand, the initial RAI dose of 150 mCi or higher was noted to be associated with repetition of RAI for PTC. Other risk factors noted were the presence of lymph nodes and distant metastasis at presentation and loco-regional uptake on the posttherapy WBS. Conversely, a negative post-treatment scan appeared to be protective against repeat RAI, as in FTC. However, multivariate analysis of risk factors showed that only metastasis at presentation (LN or distant) was associated with repeat RAI therapy.
Conclusion
The only risk factor associated with failure of initial RAI for patients with PTC and FTC in this study was distant metastasis at presentation. Nodal involvement at presentation was noted to be a significant factor for among those with PTC.
Thyroid Cancer, Papillary
;
Recurrence
2.Association of BRAF V600E mutation with tumor recurrence in a small sample of Filipino patients with papillary thyroid cancer in a single center
Harold Henrison C. Chiu ; Anna Angelica P. Macalalad-Josue ; Dianne Grace S. Corpuz ; Sahra May O. Paragas ; Oliver D. Pintor ; Michele S. Hernandez-Diwa ; Ma. Jowina H. Galarion ; Angelo D. Dela Tonga ; Patricia D. Maningat
Acta Medica Philippina 2023;57(6):40-45
Background and Objective:
Epidemiological studies have shown that Filipinos have a higher prevalence of welldifferentiated thyroid cancer and a higher rate of recurrence. The BRAF V600E mutation has been proposed as a potential prognostic marker in aggressive papillary thyroid cancers. In this study, we determined whether this mutation is a risk factor for tumor recurrence in papillary thyroid cancer among Filipinos.
Methods:
We conducted an age and sex-matched case-control study of patients with papillary thyroid cancer; we had two groups – with and without tumor recurrence – of 14 patients each, with at least a 5-year follow-up. We extracted the DNA samples from the patients’ (paraffin-embedded) tumor biopsy tissue blocks from thyroidectomy specimens, then detected the BRAF V600E mutation using polymerase chain reaction. The McNemar’s test for difference of proportions in paired data was used to determine the association of BRAF V600E mutation with recurrence.
Results:
The BRAF V600E mutation was found in 57.14% of all cases. We found a prevalence of 64.29% among those with recurrence and 50.00% among those without recurrence, with no significant difference between the two groups (p = 0.688).
Conclusion
Our study showed the BRAF V600E mutation was not associated with recurrence. We encountered
several limitations: we had limited data regarding molecular methodologies in the Philippine setting, we had a small sample size, and therefore we could not study other parameters (e.g., tumor characteristics, lymph node metastasis, stage of disease). We hope that this paves the way for future studies and collaborations to establish the role of BRAF V600E in Filipinos with papillary thyroid tumor recurrence.
papillary thyroid cancer
;
molecular diagnostics
;
tumor recurrence
3.Correlation between Contrast-enhanced Ultrasound and Risk of Tumor Recurrence in Papillary Thyroid Carcinoma.
Wen LI ; Yan ZHANG ; Qing SONG ; Yu LAN ; Hong-Ying HE ; Jun MA ; Jia-Hang ZHAO ; Yi LI ; Yu-Kun LUO
Acta Academiae Medicinae Sinicae 2021;43(3):343-349
Objective To explore the association between contrast-enhanced ultrasound and risk of tumor recurrence in papillary thyroid carcinoma(PTC). Methods A total of 287 PTCs in 287 patients who underwent surgery,conventional ultrasound,and contrast-enhanced ultrasound(CEUS)were enrolled in this study.According to 2015 American Thyroid Association(ATA)Modified Initial Risk Stratification System,the patients were categorized into three groups:low risk,intermediate risk,and high risk.The CEUS patterns of PTCs were compared between different risk stratifications. Results Hypo-enhancement was presented in 57.6% of ATA low-risk PTCs,iso-enhancement in 62.3% of ATA intermediate-risk PTCs,and hyper-enhancement in 48.2% of ATA high-risk PTCs(
Humans
;
Neoplasm Recurrence, Local/diagnostic imaging*
;
Thyroid Cancer, Papillary/diagnostic imaging*
;
Thyroid Neoplasms/diagnostic imaging*
;
Ultrasonography
4.Incidental finding of colon adenocarcinoma on I-131 whole body scan in a patient with recurrent papillary thyroid carcinoma.
Puracan Lucille T. ; Goco Gerard L. ; Ongkeko Eduardo Erasto S.
The Philippine Journal of Nuclear Medicine 2015;10(2):53-56
?Iodine-131 (I-131) whole body scan is a procedure routinely done after radioactive iodine therapy. It helps detect presence of functioning thyroid tissue remnants in the neck, as well as distant metastases. However, not all that take up I-131 are of thyroidal origin. Our patient is a 74-year-old woman with recurrent papillary thyroid carcinoma, who underwent a repeat radioactive iodine therapy (RAIT). Her post-RAIT whole body scan showed an unusual iodine-avid focus in the transverse colon which was later confirmed to be another primary malignancy of colonic origin through colonoscopy with biopsy, as well as post-surgical histopathology. This case report distinctively demonstrates uptake of I-131 in extra-thyroidal malignancy. It also emphasizes the importance of evaluating carefully any irregular-looking focal iodine uptake in areas with seemingly physiologic activity on a routine I-131 whole body-scan.
Human ; Female ; Aged ; Whole Body Imaging ; Thyroid cancer, papillary-Recurrence ; Carcinoma
5.Effect of Calcification on the Ultrasound-Guided Radiofrequency Ablation of Papillary Thyroid Carcinoma.
Yi-Ming LI ; Lin YAN ; Jing XIAO ; Ming-Bo ZHANG ; Yu-Kun LUO
Acta Academiae Medicinae Sinicae 2023;45(5):803-808
Objective To investigate the effect of calcification on the ultrasound-guided radiofrequency ablation(RFA)of papillary thyroid carcinoma(PTC).Methods We retrospectively analyzed the preoperative and follow-up data of 164 patients(182 nodules)with PTC treated by percutaneous ultrasound-guided RFA in the First Medical Center of Chinese PLA General Hospital from January 1,2018 to December 31,2021.The tumor status 12 months after RFA was taken as the endpoint event.The univariate Logistic regression analysis was employed to predict the influencing factors of incomplete ablation.The factors were then included in the multivariate Logistic regression analysis for prediction of the independent risk factors of incomplete ablation.Results The maximum nodule diameter(OR=1.16,95%CI=1.04-1.29,P=0.009)and calcification ratio >2/3(OR=19.27,95%CI=4.02-92.28,P<0.001)were the factors influencing the disappearance of lesion 12 months after RFA.Conclusions PTC with calcification can be treated with ultrasound-guided RFA.In the case of calcification ratio ≤ 2/3,this therapy demonstrates the effect equivalent to that of no calcification.
Humans
;
Thyroid Cancer, Papillary/surgery*
;
Retrospective Studies
;
Neoplasm Recurrence, Local
;
Radiofrequency Ablation/methods*
;
Calcinosis
;
Thyroid Neoplasms/pathology*
;
Ultrasonography, Interventional
6.Surgical treatment for primary papillary thyroid cancer: a Meta-analysis.
Xiaomin MENG ; Shuxin WEN ; Bingquan WANG ; Yan FENG ; Lijuan YANG ; Lingshuai KONG
Journal of Clinical Otorhinolaryngology Head and Neck Surgery 2015;29(9):835-840
OBJECTIVE:
To assess and compare the two procedures, total thyroidectomy (TT) and partial thyroidectomy (PT), for papillary thyroid cancer in terms of associated injuries, postoperative complication, recurrence rate and survival, so as to provide a reference and basis for surgical procedure option of this disease.
METHOD:
Strictly specified into the exclusion criteria, the combination of computer retrieval and manual retrieval and retrieval systems such as CNKI, Wang Fan, PubMed, central, CBM database. Total thyroidectomy and partial thyroidectomy for the treatment of patients with thyroid papillary cancer related literature were compared, with the retrieval time until December 31, 2013.
RESULT:
According to the retrieval strategy 4630 literatures were found, and 20 witch matched the exclusion criteria were left, all were retrospective study. TT and PT group of recurrent laryngeal nerve injury rate are 5.9%, 2.0% respectively [OR = 0.39, 95% CI (0.17 - 0.90), P < 0.05], TT and PT group of parathyroid injury rate are respectively 4.9%, 0.8% respectively [OR = 0.23, 95% CI (0.08 - 0.68), P < 0.01]. The TT group of 10 years survival rate is 95.24% - 100%, and the PT group is 96.8% - 99.2% [OR = 0.03, 95% CI (0 - 0.34), P < 0.01]. Unstaged, unstaged TT group' postoperative recurrence rate is 4.7%, while PT group is 12.6% [OR = 3.21, 95% CI (1.57 - 6.57), P < 0. 01]. Postoperative recurrence of stage I TT group and PT group are 4.9%, 7.8% respectively [OR = 3.82, 95% CI (1. 07-13.66) P < 0.05]; The rate of stage II TT group is 0.5%, while the rate of PT group is 15.9% [OR = 17.23, 95% CI (4.03 - 73.73), P < 0.01].
CONCLUSION
Different methods of primary thyroid papillary carcinoma surgical treatment can all obtaina good survival, but the rate of laryngeal recurrent nerve injury and parathyroid injury caused by partal throidectomy is relatively lower. As a result, partial thyroidectomy can be a good choice for early stage thyroid papillary carcinoma.
Carcinoma
;
surgery
;
Carcinoma, Papillary
;
Humans
;
Neoplasm Recurrence, Local
;
Parathyroid Glands
;
Postoperative Complications
;
Recurrent Laryngeal Nerve Injuries
;
Retrospective Studies
;
Survival Rate
;
Thyroid Cancer, Papillary
;
Thyroid Neoplasms
;
surgery
;
Thyroidectomy
;
methods
7.Short-term Outcome of T1bN0M0 Papillary Thyroid Cancer after Ultrasonography-guided Radiofrequency Ablation.
Jing XIAO ; Yu LAN ; Lin YAN ; Ming Bo ZHANG ; Yan ZHANG ; Fang XIE ; Qing SONG ; Yu Kun LUO ; Jie TANG
Acta Academiae Medicinae Sinicae 2020;42(6):771-775
Objective To investigate the short-term outcome of T1bN0M0 papillary thyroid cancer after ultrasonography-guided radiofrequency ablation(RFA). Methods Eighty-nine patients with T1bN0M0 papillary thyroid cancer who were treated with ultrasonography-guided RFA in our center from April 2014 to January 2019 were retrospectively analyzed.Trans-isthmus approach and moving shot technique were used during the RFA procedure.Ultrasonography and contrast-enhanced ultrasonography were performed before ablation,and immediately,1,3,6 and 12 months after ablation and then every 6 months thereafter. Results RFA was performed in 89 cases of papillary thyroid cancer,and no major complications were observed during the RFA.The mean follow-up was(18.8±7.3)months.The ablation zones decreased gradually during follow-up,and 38 ablation zones(42.7%)completely disappeared.The volume reduction rate was(99.2±2.3)% 30 months after ablation.During follow-up,2 patients(2.2%)developed tumor recurrence and 1 patient(1.1%)developed cervical lymph node metastasis. Conclusion Ultrasonography-guided RFA may be a safe and effective method for patients with T1bN0M0 papillary thyroid cancer.
Catheter Ablation
;
Humans
;
Lymphatic Metastasis
;
Neoplasm Recurrence, Local
;
Radiofrequency Ablation
;
Retrospective Studies
;
Thyroid Cancer, Papillary/surgery*
;
Thyroid Neoplasms/surgery*
;
Treatment Outcome
;
Ultrasonography
8.Priliminary study of pedicled sternocleidomastoid clavicular periosteocutaneous flap to repair the laryngotracheal defect.
Wen LI ; Liu YANG ; Liqing YUAN ; Deying GU
Journal of Clinical Otorhinolaryngology Head and Neck Surgery 2015;29(2):117-120
OBJECTIVE:
To investigate the feasibility of utilizing pedicled sternocleidomastoid clavicular periosteocutaneous flap to reconstruct the laryngotracheal defect after tumor resection.
METHOD:
To review 6 cases of laryngotracheal defect resulting from resction of thyroid papillary carcinoma(4/6) or subglottic laryngeal carcinoma (2/6) (T1~2N1~2M0 , UICC,2002), laryngotracheal stenting was also employed in all cases. Half a year after surgery, the stoma was sutured if no local recurrence took place and safety was proved after tracheal tube had been obstructed for days. The follow-up time lasted from half a year to 3 years.
RESULT:
Four cases (4/6) were extubated successfully without event, one case could intermittently plug the tracheal tube. One patient couldn't breath with tracheal tube plugging.
CONCLUSION
To reconstruct the laryngotracheal defect with pedicled sternocleidomastoid clavicular.periosteocutaneous flap after tumor resection is feasible in selected cases and could get satisfactory clinical results either in respiration or phonation.
Back
;
Carcinoma
;
surgery
;
Carcinoma, Papillary
;
Carcinoma, Squamous Cell
;
Clavicle
;
Head and Neck Neoplasms
;
Humans
;
Laryngeal Neoplasms
;
surgery
;
Larynx
;
Neck Muscles
;
Neoplasm Recurrence, Local
;
Reconstructive Surgical Procedures
;
Squamous Cell Carcinoma of Head and Neck
;
Stents
;
Surgical Flaps
;
Thyroid Cancer, Papillary
;
Thyroid Neoplasms
;
surgery
9.Clinical features and prognoses of re-operated patients for persistent/recurrent papillary thyroid carcinoma.
Nan XU ; Yong Cong CAI ; Rong Hao SUN ; Bin Tao HU ; Lei LIU ; Yu Qing XIANG ; Wang Hu ZHENG ; Xiao Lei CHEN ; Gang QIN ; Xu WANG ; Chun Yan SHUI ; Yu Dong NING ; Yu Qiu ZHOU ; Chao LI
Chinese Journal of Otorhinolaryngology Head and Neck Surgery 2022;57(9):1052-1058
Objective: To investigate the clinicopathological characteristics and the survival of re-operated patients for persistent/recurrent papillary thyroid carcinoma (PTC) and risk factors for re-recurrence after the second operation. Method: A retrospective analysis of 69 cases underwent re-operation for persistent/recurrent PTC in Sichuan Cancer Hospital from January 2010 to December 2016 was performed. There were 21 males and 48 females, aged 14-85 (44.8) years old. According to the imaging after initial treatment, they were divided into a recurrence group (42 cases) and a persistent disease/residual group (27 cases). The positive rates of ipsilateral paratracheal lymph node metastases at re-operation were calculated and compared by chi-square test. Patients were divided into different subgroups according to potential risk factors for re-recurrence. Kaplan-Meier (K-M) method was used for survival analysis. Results: The positive rate of ipsilateral paratracheal lymph node metastasis in recurrence group (15/42, 35.7%) was significantly lower than that in the persistent disease/residual group (17/27, 63.0%) (χ2=4.91, P<0.05). The follow-up period after re-operation was 60-104 months, with a median of 66 months, and 8 patients were lost to follow-up. Permanent hypoparathyroidism occurred in 2 cases (2.9%) and permanent recurrent laryngeal nerve palsy in 1 case (1.4%). Twenty patients had structural recurrences and/or distant metastases. The 5-year disease-specific survival rate was 92.8% and the 5-year recurrence-free survival rate was 68.1%. Survival analysis was performed on risk factors such as age≥55 years old, recurrent tumor diameter ≥4 cm, number of positive lymph nodes ≥ 10, and obvious extracapsular invasion (ENE). Among them, age and diameter of recurrent tumor had significant influences on recurrence-free survival rate (χ2 was 6.36, 8.17, respectively, both P values<0.05). There was a statistically significant difference in recurrence-free survival rates between ENE(+) group and ENE(-) group (χ2=5.52, P<0.05). Conclusion: For the re-operated patients due to persistence/ recurrence PTC, attention should be paid to protecting the parathyroid gland and recurrent laryngeal nerve during re-operation. Timely and effective postoperative follow-up for patients aged ≥ 55 years, with recurrent tumor diameter ≥ 4 cm and ENE(+), can significantly improve their prognoses.
Adult
;
Carcinoma/pathology*
;
Carcinoma, Papillary/surgery*
;
Female
;
Humans
;
Lymphatic Metastasis
;
Male
;
Middle Aged
;
Neck Dissection
;
Neoplasm Recurrence, Local/surgery*
;
Prognosis
;
Retrospective Studies
;
Thyroid Cancer, Papillary/surgery*
;
Thyroid Neoplasms/pathology*
;
Thyroidectomy/adverse effects*
10.Analysis of risk factors for recurrence of differentiated thyroid carcinoma after surgical resection combined with iodine-131 and TSH suppression therapy.
Ting YE ; Shengwei LAI ; Baolin CAO ; Baixuan XU ; Ruimin WANG
Journal of Clinical Otorhinolaryngology Head and Neck Surgery 2023;37(5):370-374
Objective:To investigate the risk factors of recurrence after surgical resection of differentiated thyroid carcinoma combined with iodine-131 and TSH(Thyroid stimulating hormone) inhibition therapy. Methods:From January 2015 to April 2020, the clinical data of patients with structural recurrence and without recurrence were retrospectively collected after surgical treatment combined with iodine-131 and TSH inhibition therapy in the First Medical Center of PLA General Hospital. The general conditions of the two groups of patients were analyzed and the measurement data in line with the normal distribution was used for comparison between groups. For measurement data with non-normal distribution, the rank sum test was used for inter-group comparison. The Chi-square test was used for comparison between the counting data groups. Univariate and multivariate regression analyses were used to determine the risk factors associated with relapse. Results:The median follow-up period was 43 months(range 18-81 months) and 100 patients(10.5%) relapsed among the 955 patients. Univariate analysis showed that tumor size, tumor multiple, the number of lymph node metastases>5 in the central region of the neck, and the number of lymph node metastases>5 in the lateral region were significantly correlated with post-treatment recurrence(P<0.001, P=0.018, P<0.001, P<0.001). Multivariate analysis showed that tumor size(adjusted odds ratio OR: 1.496, 95%CI: 1.226-1.826, P<0.001), tumor frequency(adjusted odds ratio OR: 1.927, 95%CI: 1.003-3.701, P=0.049), the number of lymph node metastases in the central neck region>5(adjusted odds ratio OR: 2.630, 95%CI: 1.509-4.584, P=0.001) and the number of lymph node metastases in the lateral neck region>5(adjusted odds ratio OR: 3.074, 95%CI: 1.649-5.730, P=0.001) was associated with tumor recurrence. Conclusion:The study showed that tumor size, tumor multiple, the number of lymph node metastases in the central region of the neck>5 and the number of lymph node metastases in the side of the neck >5 are independent risk factors for recurrence of differentiated thyroid cancer after surgical resection combined with iodine-131 and TSH inhibition therapy.
Humans
;
Thyroid Cancer, Papillary/surgery*
;
Lymphatic Metastasis/pathology*
;
Retrospective Studies
;
Neck Dissection
;
Thyroidectomy/adverse effects*
;
Neoplasm Recurrence, Local/pathology*
;
Thyroid Neoplasms/surgery*
;
Risk Factors
;
Adenocarcinoma
;
Thyrotropin
;
Lymph Nodes/pathology*